
    
      This is a single centre, open-label, non-randomised single dose study in healthy male
      subjects. Each subject will receive a single 15 min IV administration of 14C labelled
      elacytarabine.

      In this study, at least 6 subjects will be dosed in order to obtain data in 4 evaluable
      subjects.
    
  